Dopamine deficiency in mice

Brain and Development

Volumn 22, Issue SUPPL. 1, 2000, Pages 54-60

  Kobayashi, Kazuto ^a   Sano, Hiromi ^b  

^a Institute of Biomedical Sciences   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Dopamine; Emotional learning; Gene targeting; Motor control; Transgenic mouse; Tyrosine hydroxylase

Indexed keywords

DOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; AVOIDANCE BEHAVIOR; BEHAVIOR; CONFERENCE PAPER; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ENZYME DEFICIENCY; HYPOPHYSIS FUNCTION; LOCOMOTION; MOUSE; MOUSE MUTANT; NONHUMAN; PHENOTYPE; POSTNATAL DEVELOPMENT;

EID: 0033843532     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0387-7604(00)00134-0     Document Type: Conference Paper

References (27)

1. Riederer P., Sofic E., Konradi C., Kornhuber J., Beckmann H., Dietl M., et al. The role of dopamine in the control of neurobiological functions. Flückiger E., Müller E.E., Thorner M.O., et al. The role of brain dopamine. 1985;1-17 Springer-Verlag, Berlin.
2. Nagatsu T., Yamaguchi T., Rahman M.K., Trocewicz J., Oka K., Hirata Y., et al. Catecholamine-related enzymes and the biopterin cofactor in Parkinson's disease and related extrapyramidal diseases. Hassler R.G., Christ J.F., et al. Advances in neurology. 1984;467-473 Raven Press, New York.
3. Segawa M., Nomura Y., Kase M. Diurnally fluctuating hereditary progressive dystonia. Vinken P.J., Bruyn G.W., Klawans H.L. Handbook of clinical neurology. 1986;529-539 Elsevier, New York.
4. Davidson M., Keefe R.S.E., Mohs R.C., Siever L.J., Losonczy M.F., Horvath T.B., Davis K.L. L-DOPA challenge and relapse in schizophrenia. Am J Psychiatry. 122:1987;509-522.
5. Lindvall O., Bjöklund A. Dopamine- and norepinephrine-containing neuron systems: their anatomy in the rat brain. Emson P.C. Chemical neuroanatomy. 1983;229-255 Raven Press, New York.
6. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci. 15:1992;285-320.
7. Le Moal M., Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev. 71:1991;155-234.
8. Moore K.E., Lookingland K.J. Dopaminergic neuronal systems in the hypothalamus. Bloom F.E., Kupfer D.J. Psychopharmacology. 1995;245-256 Raven Press, New York.
9. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 13:1992;220-240.
10. Gary K.A., Chronwall B.M. The onset of dopaminergic innervation during ontogeny decreases melanotrope proliferation in the intermediate lobe of the rat pituitary. Int J Dev Neurosci. 10:1992;131-142.
11. Ben-Jonathan N., Arbogast L.A., Hyde J.F. Neuroendocrine regulation of prolactin release. Prog Neurobiol. 33:1989;399-447.
12. Beaulieu M., Goldman M.E., Miyazaki K., Frey E.A., Eskay R.L., Kebabian J.W., Cote T.E. Bromocriptine-induced changes in the biochemistry, physiology, and histology of the intermediate lobe of the rat pituitary gland. Endocrinology. 114:1984;1871-1884.
13. Loeffer J.-P., Demeneix B.A., Kley N.A., Höllt V. Dopamine inhibition of proopiomelanocortin gene expression in the intermediate lobe of the pituitary. Neuroendocrinology. 47:1988;95-101.
14. Nishii K., Matsushita N., Sawada H., Sano H., Noda Y., Mamiya T., et al. Motor and learning dysfunction during postnatal development in mice defective in dopamine neuronal transmission. J Neurosci Res. 54:1998;450-464.
15. Kobayashi K., Morita S., Sawada H., Mizuguchi T., Yamada K., Nagatsu I., et al. Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice. J Biol Chem. 270:1995;27235-27243.
16. Hu S.C., Chang F.W., Sung Y.J., Hsu W.H., Lee E.H.Y. Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice. J Pharmacol Exp Ther. 259:1991;1379-1387.
17. Kelly P.H., Iversen S.D. Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol. 40:1976;45-56.
18. Koob G.F., Riley S.J., Smith S.C., Robbins T.W. Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi and olfactory tubercle on feeding, locomotor activity, and amphetamine anorexia in the rat. J Comp Physiol Psychol. 92:1978;917-927.
19. Dunstan R., Broekkamp C.L., Lloyd K.G. Involvement of caudate nucleus, amygdala, or reticular formation in neuroleptic and narcotic catalepsy. Pharmacol Biochem Behav. 14:1980;168-174.
20. Fibiger H.C., Zis A.P., Phillips A.G. Haloperidol-induced disruption of conditioned avoidance responding: attenuation by prior training or by anticholinergic drugs. Eur J Pharmacol. 30:1975;309-314.
21. Koob G.F., Simon H., Herman J.P., Le Moal M. Neuroleptic-like disruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems. Brain Res. 303:1984;319-329.
22. McCullough L.D., Sokolowski J.D., Salamone J.D. A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance. Neuroscience. 52:1993;919-925.
23. Everitt B., Morris K., O'Brien A., Robbins T.W. The basolateral amygdala-central striatal system and conditioned place preference: further evidence of limbic-striatal interactions underlying reward-related processes. Neuroscience. 42:1991;1-18.
24. Neve K.A., Loeschen S., Marshall J.F. Denervation accelerates the reappearence of neostriatal D-2 receptors after irreversible receptor blockade. Brain Res. 329:1985;225-231.
25. Martres M.P., Sokoloff P., Giros B., Schwartz J.C. Effects of dopaminergic transmission interruption on the D2 receptor isoforms in various cerebral tissues. J Neurochem. 58:1992;673-679.
26. Ellias K.A., Weiner R.I. Inhibition of estrogen-induced anterior pituitary enlargement and arteriogenesis by bromocriptine in Fischer 344 rats. Endocrinology. 120:1987;617-621.
27. Proulx-Ferland L., Labrie F., Dumont D., Côté J., Coy D.H., Sveiraf J. Corticotropin-releasing factor stimulates secretion of melanocyte-stimulating hormone from the rat pituitary. Science. 217:1982;62-63.